Regulatory News:

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an extraordinary shareholders’ meeting on June 30, 2025.

As previously disclosed, GeNeuro is subject to a definitive debt-restructuring moratorium granted by the Geneva Tribunal of First Instance on 26 May 2025. In this context, the Company is not in a position to finalize and present its audited annual accounts for the financial year ending 31 December 2024. Consequently, it cannot hold its Ordinary Annual General Meeting within six months of year-end, as required under Swiss corporate law.

Pursuant to the Company’s Articles of Association and applicable Swiss legal provisions, the mandates of the current members of the Board of Directors will expire on 30 June 2025. To ensure continuity of governance, the Extraordinary General Meeting has been convened to vote on the re-election of the Board members, of the Chairman, of the Remuneration Committee, and of the Independent Proxy until the next Annual General Meeting can be held.

The notice to the meeting is published today in the Swiss Official Gazette of Commerce.

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.

For more information, visit: www.geneuro.com

Disclaimer

This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law..

GeNeuro Jesús Martin-Garcia Chairman and CEO investors@geneuro.com

GeNeuro (EU:GNRO)
Gráfico Histórico do Ativo
De Jun 2025 até Jul 2025 Click aqui para mais gráficos GeNeuro.
GeNeuro (EU:GNRO)
Gráfico Histórico do Ativo
De Jul 2024 até Jul 2025 Click aqui para mais gráficos GeNeuro.